A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT07023354
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Tranquil Clinical Research, Houston, Texas, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
- Conditions
- Borderline Personality DisorderAttention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT07001475
A Study to Test How Well Multiple Doses of BI 3810477 Are Tolerated by Healthy Adults
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT06984926
A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT06962826
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum, Biberach/Riß, Germany
A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON)
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 285
- Registration Number
- NCT06962852
- Locations
- 🇫🇷
HOP Gui de Chauliac, Montpellier, France
🇫🇷HOP Necker, Paris, France
🇮🇹Istituto G. Gaslini, Genova, Italy
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 300
- Registration Number
- NCT06962839
- Locations
- 🇺🇸
Retina Consultants Of Texas, The Woodlands, Texas, United States
🇺🇸Retinal Consultants Medical Group, Inc, Modesto, California, United States
🇺🇸Retina Consultants of San Diego, Poway, California, United States
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT06957756
- Locations
- 🇺🇸
Omega Research Orlando, LLC, Orlando, Florida, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
🇺🇸Arizona Liver Health, Act Medical Park Clinic, Chandler, Arizona, United States
A Study in Healthy People to Test How 3 Different Formulations of BI 764198 Are Taken up in the Body and How This is Influenced by Food
- Conditions
- Healthy
- Interventions
- Drug: BI 764198, formulation 1Drug: BI 764198, formulation 2Drug: BI 764198, formulation 3
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06955754
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach/Riss, Germany
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2025-04-20
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4200
- Registration Number
- NCT06935370
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Mobile, Alabama, United States
🇺🇸Drug Research and Analysis Corporation, Montgomery, Alabama, United States
🇺🇸Valley Clinical Trials, Inc., Covina, California, United States
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2025-04-14
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 416
- Registration Number
- NCT06926660
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Orange County Clinical Trials, Anaheim, California, United States
🇺🇸North America Research Institute, San Dimas, California, United States